EA201200890A1 - Комбинированная терапия hcv - Google Patents
Комбинированная терапия hcvInfo
- Publication number
- EA201200890A1 EA201200890A1 EA201200890A EA201200890A EA201200890A1 EA 201200890 A1 EA201200890 A1 EA 201200890A1 EA 201200890 A EA201200890 A EA 201200890A EA 201200890 A EA201200890 A EA 201200890A EA 201200890 A1 EA201200890 A1 EA 201200890A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- hcv
- treatment
- methods
- hcv therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Настоящее изобретение относится к способам, включающим введение комбинации соединения (1), указанного ниже, особенно его кристаллических форм и его фармацевтически приемлемых солей по крайней мере с одним дополнительным соединением, подавляющим HCV, описанным далее в описании, для лечения инфекционного вируса гепатита С (HCV). Указанные способы осуществляют путем введения соединения (1) и по крайней мере одного дополнительного соединения, подавляющего HCV, в отдельности или совместно, включая курс лечения.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28800409P | 2009-12-18 | 2009-12-18 | |
US31734310P | 2010-03-25 | 2010-03-25 | |
PCT/CA2010/001935 WO2011072370A1 (en) | 2009-12-18 | 2010-12-13 | Hcv combination therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201200890A1 true EA201200890A1 (ru) | 2013-01-30 |
Family
ID=44166675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200890A EA201200890A1 (ru) | 2009-12-18 | 2010-12-13 | Комбинированная терапия hcv |
Country Status (14)
Country | Link |
---|---|
US (3) | US20130029904A1 (ru) |
EP (1) | EP2512477A4 (ru) |
JP (1) | JP5536229B2 (ru) |
KR (1) | KR20120116404A (ru) |
CN (1) | CN102753173A (ru) |
AU (1) | AU2010333656B2 (ru) |
BR (1) | BR112012014729A2 (ru) |
CA (1) | CA2784646A1 (ru) |
CL (1) | CL2012001449A1 (ru) |
EA (1) | EA201200890A1 (ru) |
IL (1) | IL219696A0 (ru) |
MX (1) | MX2012007076A (ru) |
NZ (1) | NZ599963A (ru) |
WO (1) | WO2011072370A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2782950A1 (en) | 2009-12-18 | 2011-06-23 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
JP5763673B2 (ja) | 2009-12-18 | 2015-08-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | mGluR5受容体のアロステリック調節因子としての二環式チアゾール |
US9243025B2 (en) * | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
LT2709613T (lt) * | 2011-09-16 | 2018-02-12 | Gilead Pharmasset Llc | Žmogaus hepatito viruso (hcv) gydymo būdai |
WO2013045460A1 (en) * | 2011-09-27 | 2013-04-04 | Novartis Ag | Alisporivr for treatment of hepatis c virus infection |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
TW201600087A (zh) | 2011-10-21 | 2016-01-01 | 艾伯維有限公司 | 治療c型肝炎病毒(hcv)的方法 |
DK2583677T1 (da) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Fremgangsmåder til behandling af HCV omfattende mindst to direktevirkende antivirale midler, ribavirin, men ikke inteferon |
JPWO2013183683A1 (ja) * | 2012-06-06 | 2016-02-01 | Dic株式会社 | 液晶組成物 |
SG11201502802PA (en) | 2012-10-19 | 2015-05-28 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
CN103145811B (zh) * | 2013-03-15 | 2014-05-07 | 深圳翰宇药业股份有限公司 | 一种合成阿拉泊韦的方法 |
US20170196775A1 (en) * | 2014-06-11 | 2017-07-13 | Jeremy Nelson | Novel delivery devices and methods |
WO2017062840A1 (en) * | 2015-10-09 | 2017-04-13 | Trek Therapeutics, Pbc | Combination therapy for the treatment of hepatitis c virus |
JP7129703B2 (ja) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用 |
EP3454862A4 (en) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
WO2020037530A1 (en) * | 2018-08-22 | 2020-02-27 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Crystalline form of compound and uses thereof in medicine |
EP3893914B1 (en) * | 2018-12-14 | 2024-03-20 | Waterstone Pharmaceuticals (Wuhan) Co., Ltd. | Maleate of scy-635 and uses thereof in medicine |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2255275T3 (es) * | 1998-07-01 | 2006-06-16 | Debiopharm S.A. | Nueva ciclosporina con perfil de actividad mejorado. |
DE60221627D1 (de) | 2001-12-21 | 2007-09-20 | Virochem Pharma Inc | Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren |
ES2320771T3 (es) * | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
JP4447603B2 (ja) * | 2003-05-21 | 2010-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビター化合物 |
LT2604620T (lt) | 2003-05-30 | 2016-09-12 | Gilead Pharmasset Llc | Modifikuoti fluorintų nukleozidų analogai |
US20050222198A1 (en) | 2003-12-22 | 2005-10-06 | K.U. Leuven Research & Development, Gerhard Puerstinger And Gilead Sciences, Inc. | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment |
PT1781662E (pt) * | 2004-08-18 | 2011-07-01 | Pfizer | Inibidores de rna polimerase dependendte de rna do vírus da hepatitie c e composições e tratamentos usando os mesmos |
CA2583494C (en) * | 2004-10-01 | 2014-01-21 | Scynexis, Inc. | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection |
GT200500373A (es) | 2004-12-17 | 2006-10-02 | Compuestos de piridazinones | |
DK1824482T3 (en) | 2004-12-17 | 2014-03-24 | Anadys Pharmaceuticals Inc | AND 3,5-disubstituted 3,5,7-trisubstituted-3H-oxazolo AND 3H-thiazolo [4,5-d] pyrimidin-2-one compounds and prodrugs thereof |
BRPI0519345A2 (pt) * | 2004-12-23 | 2009-01-20 | Novartis Ag | composiÇço para tratamento do hcv |
GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2007150001A1 (en) | 2006-06-22 | 2007-12-27 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
DK2038275T3 (da) * | 2006-07-07 | 2010-05-10 | Gilead Sciences Inc | Ny pyridazinforbindelse og anvendelse heraf |
US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7659270B2 (en) | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG176488A1 (en) * | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US7964580B2 (en) * | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
UA99466C2 (en) | 2007-07-06 | 2012-08-27 | Гилиад Сайенсиз, Инк. | Crystalline pyridazine compound |
US8629171B2 (en) | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
US8178548B2 (en) * | 2007-09-17 | 2012-05-15 | Abbott Laboratories | Anti-infective agents and uses thereof |
CA2729168A1 (en) | 2008-07-02 | 2010-02-04 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
TWI480272B (zh) | 2008-10-09 | 2015-04-11 | Anadys Pharmaceuticals Inc | 藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法 |
-
2010
- 2010-12-13 AU AU2010333656A patent/AU2010333656B2/en not_active Ceased
- 2010-12-13 CA CA2784646A patent/CA2784646A1/en not_active Abandoned
- 2010-12-13 MX MX2012007076A patent/MX2012007076A/es unknown
- 2010-12-13 KR KR1020127014548A patent/KR20120116404A/ko active Search and Examination
- 2010-12-13 BR BR112012014729A patent/BR112012014729A2/pt not_active Application Discontinuation
- 2010-12-13 CN CN201080063518XA patent/CN102753173A/zh active Pending
- 2010-12-13 JP JP2012543421A patent/JP5536229B2/ja not_active Expired - Fee Related
- 2010-12-13 NZ NZ599963A patent/NZ599963A/en not_active IP Right Cessation
- 2010-12-13 EP EP10836873.9A patent/EP2512477A4/en not_active Withdrawn
- 2010-12-13 WO PCT/CA2010/001935 patent/WO2011072370A1/en active Application Filing
- 2010-12-13 US US13/515,967 patent/US20130029904A1/en not_active Abandoned
- 2010-12-13 EA EA201200890A patent/EA201200890A1/ru unknown
-
2012
- 2012-05-09 IL IL219696A patent/IL219696A0/en unknown
- 2012-06-01 CL CL2012001449A patent/CL2012001449A1/es unknown
-
2015
- 2015-02-26 US US14/632,554 patent/US20150164884A1/en not_active Abandoned
-
2016
- 2016-03-31 US US15/086,121 patent/US20160206678A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ599963A (en) | 2014-02-28 |
EP2512477A1 (en) | 2012-10-24 |
JP5536229B2 (ja) | 2014-07-02 |
CA2784646A1 (en) | 2011-06-23 |
JP2013514276A (ja) | 2013-04-25 |
CN102753173A (zh) | 2012-10-24 |
US20130029904A1 (en) | 2013-01-31 |
EP2512477A4 (en) | 2013-07-10 |
AU2010333656B2 (en) | 2015-08-27 |
WO2011072370A1 (en) | 2011-06-23 |
KR20120116404A (ko) | 2012-10-22 |
US20150164884A1 (en) | 2015-06-18 |
MX2012007076A (es) | 2012-07-20 |
AU2010333656A1 (en) | 2012-06-07 |
IL219696A0 (en) | 2012-07-31 |
BR112012014729A2 (pt) | 2016-03-29 |
CL2012001449A1 (es) | 2012-08-17 |
US20160206678A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201200890A1 (ru) | Комбинированная терапия hcv | |
PH12018550201A1 (en) | Hepatitis b antiviral agents | |
MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
PH12018550148A1 (en) | Hepatitis b antiviral agents | |
EA201391519A1 (ru) | 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний | |
WO2012142093A3 (en) | 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases | |
EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
MX2012004032A (es) | Compuestos para el tratamiento de hepatitis c. | |
MX2012000959A (es) | Inhibidores de los virus flaviviridae. | |
WO2012018534A3 (en) | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases | |
MY160130A (en) | Hepatitis c virus inhibitors | |
PH12020550065A1 (en) | Hepatitis b antiviral agents | |
MX2013003634A (es) | Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales. | |
EA201301158A1 (ru) | Противовирусные соединения | |
TN2012000358A1 (en) | Hepatitis c virus inhibitors | |
PH12015501560A1 (en) | Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases | |
MX2013006475A (es) | Inhibidores macrociclicos de virus flaviviridae. | |
EA201290575A1 (ru) | Ингибиторы вирусов flaviviridae | |
EP2555622A4 (en) | HEPATITIS C-VIRUS HEMMER | |
MX2012008211A (es) | Inhibidores de virus flaviviridae. | |
UA102677C2 (ru) | Хиноксалинсодержащие соединения как ингибиторы вируса гепатита с | |
IN2012DN01855A (ru) | ||
MX350746B (es) | Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral. | |
JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
MX2013003060A (es) | Terapia de combinacion para tratar infeccion por hcv. |